Key facts
- This page summarizes Charles R. Romp's Form 4 filing for Seagen Inc..
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 15 Dec 2023, 18:16.
Charles R. Romp - 14 Dec 2023 Form 4 Insider Report for Seagen Inc.
- Reporting relationship
- EVP, Commercial U.S.
- Issuer ticker
- N/A
- Reported as of
- 14 Dec 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 15 Dec 2023, 18:16:13 UTC
- Prior SEC filing
- 22 Sep 2023
- Next SEC filing
- 13 Feb 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jennifer Prosba, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Charles R. Romp filed Form 4 for Seagen Inc. on 15 Dec 2023.
Change
- Previous filing in this sequence was filed on 22 Sep 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SGEN
transaction
Derivative
Performance Stock Units
Disposed to Issuer
- Transaction value
- Shares
- -1,747
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 14 Dec 2023
- Ownership
- Direct
- Underlying class
- Common stock
- Underlying amount
- 1,747
- Exercise price
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Charles R. Romp is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 2 footnotes
Footnote F1
Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger").
Footnote F2
Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit granted in August 2023 (each, a "Company August 2023 PSU") that was unvested as of immediately prior to the Effective Time, was cancelled and converted into the right to receive a Parent cash-based award with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company August 2023 PSU, based on target performance.